Eli Lilly (LLY) — Upcoming Catalysts
FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Eli Lilly, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.
For informational purposes only — not investment advice. Track LLY live on Mooboard →
This week2
- Oct 2026ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutRetatrutide · Phase 3 · Type 2 DiabetesNCT06297603: Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3). Primary completion 2026-10 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 2026ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutBaricitinib · Phase 3 · Systemic Juvenile Idiopathic ArthritisNCT04088396: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA). Primary completion 2026-10 (estimated); status ACTIVE_NOT_RECRUITING.
31–90 days6
- Nov 2026ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutTirzepatide · Phase 3 · Type 1 Diabetes; ObesityNCT06914895: A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight. Primary completion 2026-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 2026ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutLY3938577 · Phase 2 · Diabetes Mellitus, Type 2NCT07215312: A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin. Primary completion 2026-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 2026ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutLY4515100 · Phase 2 · Acute Pain; MolarNCT07511816: A Study of LY4515100 in Participants With Pain Following Third Molar Removal. Primary completion 2026-11 (estimated); status RECRUITING.
- Nov 2026ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutRetatrutide · Phase 3 · ObesityNCT06662383: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity. Primary completion 2026-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 2026ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutTirzepatide · Phase 3 · Type 1 Diabetes; ObesityNCT06962280: A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight. Primary completion 2026-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 2026ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutLY3537021 · Phase 2 · Nausea; VomitingNCT07169851: A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer. Primary completion 2026-12 (estimated); status RECRUITING.
Later17
- Feb 2027ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutAbemaciclib · Phase 2 · GliomaNCT06413706: A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy. Primary completion 2027-02 (estimated); status ACTIVE_NOT_RECRUITING.
- Feb 2027ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutOrforglipron · Phase 3 · Obesity; OverweightNCT06672549: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040). Primary completion 2027-02 (estimated); status RECRUITING.
- Feb 2027ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutBrenipatide · Phase 2 · SmokingNCT07223840: A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse. Primary completion 2027-02 (estimated); status RECRUITING.
- Mar 2027ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutMacupatide · Phase 2 · Obesity; OverweightNCT07215559: A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes. Primary completion 2027-03 (estimated); status RECRUITING.
- Mar 2027ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutSolbinsiran · Phase 2 · Severe HypertriglyceridemiaNCT07269210: A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia. Primary completion 2027-03 (estimated); status RECRUITING.
- Apr 2027ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutLY4065967 · Phase 2 · Chronic Pain; Low Back PainNCT07641504: A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain. Primary completion 2027-04 (estimated); status RECRUITING.
- Apr 2027ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutLY3537982 · Phase 1 / Phase 2 · Carcinoma, Non-Small-Cell Lung; Colorectal NeoplasmsNCT04956640: Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C). Primary completion 2027-04 (estimated); status ACTIVE_NOT_RECRUITING.
- Apr 2027ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutLY3016859 ISA · Phase 2 · Osteoarthritis, Knee; Diabetic Neuropathic PainNCT05986292: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain. Primary completion 2027-04 (estimated); status RECRUITING.
- Apr 2027ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutLY4065967 · Phase 2 · Osteoarthritis, Knee; Chronic PainNCT07641517: A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain. Primary completion 2027-04 (estimated); status RECRUITING.
- May 2027ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutLY4268989 · Phase 2 · Ulcerative ColitisNCT07186101: LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:. Primary completion 2027-05 (estimated); status RECRUITING.
- May 2027ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutOrforglipron · Phase 3 · Diabetes Mellitus, Type 2; Diabetes MelletusNCT07613307: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting. Primary completion 2027-05 (estimated); status RECRUITING.
- May 2027ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutLY4005130 · Phase 2 · Vitiligo; Non-Segmental Vitiligo (NSV)NCT07533019: A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo. Primary completion 2027-05 (estimated); status RECRUITING.
- May 2027ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutLY3457263 · Phase 2 · Type 2 DiabetesNCT06897475: A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide. Primary completion 2027-05 (estimated); status RECRUITING.
- May 2027ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutRamucirumab · Phase 2 · Neoplasms; ChildNCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer. Primary completion 2027-05 (estimated); status RECRUITING.
- May 2027ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutLY3650150 · Phase 3 · Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)NCT06338995: A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP). Primary completion 2027-05 (estimated); status RECRUITING.
- May 2027ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutClazakizumab · Phase 2 · Atherosclerosis; Cardiovascular DiseaseNCT07783802: A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event. Primary completion 2027-05 (estimated); status RECRUITING.
- Jun 2027ClinicalTrials.gov ↗Eli Lilly(LLY)Phase 2/3 readoutLY4005130 · Phase 2 · Alopecia AreataNCT07533006: A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss). Primary completion 2027-06 (estimated); status RECRUITING.
How Eli Lilly has moved — past-year price reactions
How binary is LLY? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.
1.3%
1
35.9%
249
Largest single-day moves
- +10.3%2026-02-04no matched headline
- +9.8%2026-04-30no matched headline
- +8.2%2025-10-01no matched headline
- -7.8%2026-02-05no matched headline
- +7.1%2026-06-26no matched headline
- -5.9%2026-03-17no matched headline
Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.
Eli Lilly — active clinical pipeline
Eli Lilly's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.
89 assets163 programsPh1 61Ph2 41Ph3 52· 9 post-marketing (Ph4)
AreasOncologyAutoimmuneImmunologyMetabolicNeuroscienceCardiovascularOphthalmologyOther
AbemaciclibOncology · CDK4/6
Phase 1
Phase 2
EloralintideMetabolic
Phase 1
OrforglipronMetabolic
BrenipatideNeuroscience · GIP/GLP-1disclosed↗
Phase 1
TirzepatideMetabolic · GIP/GLP-1
Phase 2
RetatrutideMetabolic · glucagon/GIP/GLP-1
Phase 1
BaricitinibMetabolic · JAK1/2
SelpercatinibOncology · RET
DonanemabNeuroscience · amyloid-β
Phase 2
RamucirumabOncology · VEGFR2
VepugratinibOncology
Phase 1
Phase 2
Phase 3
GalcanezumabNeuroscience · CGRP
LY3650150Immunology
[Lu-177]-PNT2002Oncology
IxekizumabAutoimmune · IL-17A
Phase 3
LebrikizumabImmunology · IL-13
Phase 3
LepodisiranCardiovascular
Phase 3
Lepodisiran SodiumCardiovascular
LY4064809Oncology
Phase 3
RemternetugNeuroscience
Phase 3
Sofetabart MipitecanOncology
Phase 3
LY4005130Autoimmune
Phase 2
LY4065967Other
120 mg LY2784544Oncology
Phase 2
BimagrumabMetabolic · ACVR2B
Phase 2
EltrekibartAutoimmune
Phase 2
LOXO-292Oncology · RET
Phase 2
LY3016859 ISAOther
Phase 2
LY3305677Metabolic
Phase 2
LY3457263Metabolic
Phase 2
LY3537021Other
Phase 2
LY4395089Autoimmune
Phase 2
LY4515100Other
Phase 2
Mirikizumab - Intravenous (IV)Autoimmune
Phase 2
MORF-057Autoimmune
PirtobrutinibOncology · BTK
Phase 2
SolbinsiranMetabolic
Phase 2
STX-478Oncology
Phase 2
LY3484356Oncology
LY4256984Neuroscience
[Ac-225]-PSMA-62 (mCRPC)Oncology
Phase 1
Abemaciclib Tablet (Test Formulation)Other
Phase 1
LOXO-783Oncology
Phase 1
LY2835219Oncology · CDK4/6
Phase 1
LY3200882Oncology
Phase 1
LY3295668 ErbumineOncology
Phase 1
LY3410738Oncology
Phase 1
LY3439539Neuroscience
Phase 1
LY3962673Oncology
LY3971297Cardiovascular
Phase 1
LY3981314Other
Phase 1
LY4006895Neuroscience
Phase 1
LY4006896Neuroscience
Phase 1
LY4050784Oncology
Phase 1
LY4052031Oncology
Phase 1
LY4057996 SCMetabolic
Phase 1
LY4066434.Oncology
LY4066708Oncology
Phase 1
LY4088044Other
Phase 1
LY4152199 - IVOncology
Phase 1
LY4167586Metabolic
Phase 1
LY4174794Metabolic
Phase 1
LY4175408Oncology
LY4178256Other
Phase 1
LY4213663Autoimmune
Phase 1
LY4214835Oncology
Phase 1
LY4226695Other
Phase 1
LY4257496Oncology
Phase 1
LY4298445Autoimmune
Phase 1
LY4302814Other
Phase 1
LY4329090Metabolic
Phase 1
LY4337713Oncology
Phase 1
LY4355756Other
Phase 1
LY4405094Neuroscience
Phase 1
LY4515100 via SADOther
Phase 1
LY4584180Oncology
Phase 1
LY5625575Other
Phase 1
LY5830966Oncology
Phase 1
Sofe-MOncology
Phase 1
TersolisibOther
Phase 1
Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).
Targets from a ChEMBL (EMBL-EBI) snapshot dated 2026-08-20 · 310/1701 assets resolved when it was built
Dotted targets marked disclosed↗aren't yet in ChEMBL — they're taken from a company/regulatory disclosure; click the marker for the source.
See the full biopharma catalyst calendar across all covered companies.